Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.

@article{Ludwig2013RandomizedPI,
  title={Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.},
  author={Heinz Ludwig and Lu{\'i}sa Viterbo and Richard Greil and Tamas Masszi and Ivan {\vS}pi{\vc}ka and Ofer Shpilberg and Roman Hajek and Anna Dmoszyńska and Bruno Paiva and Mar{\'i}a Bel{\'e}n Vidriales and Graça Vasconcelos Esteves and Anne Marie Stoppa and D. O. Robinson and Deborah L. Ricci and Andrew Cakana and Christopher Enny and Huaibao Feng and Helgi J K van de Velde and J. -L. Harousseau},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2013},
  volume={31 2},
  pages={247-55}
}
PURPOSE Bortezomib-thalidomide-dexamethasone (VTD) is an effective induction therapy in multiple myeloma (MM). This phase II, noncomparative study sought to determine whether addition of cyclophosphamide to this regimen (VTDC) could further increase efficacy without compromising safety. PATIENTS AND METHODS Patients age 18 to 70 years with previously… CONTINUE READING